Additionally, it is important to explore whether the duration and cumulative dose of cytoreductive therapy affect the incidence of SSC, confirm the potential protective IFN role, and identify other factors that may contribute to the development of SSC. The gene discussed is IFNA1; the disease is systemic sclerosis.